期刊文献+

关于加快建立我国孤儿药政策的建议 被引量:5

Accelerate the Establishment of Orphan Drugs Policy
下载PDF
导出
摘要 目的:了解我国罕见病及孤儿药现状,借鉴国际孤儿药管理制度的成功经验对建立我国孤儿药政策提出建议。方法:通过文献检索比较分析国外孤儿药管理制度,根据我国孤儿药存在的问题,提出政策制定方法。结果:通过我国罕见病及孤儿药现状及其国际相关政策法规的成功经验的概述,来引起社会更多的关注,提高专业人士对罕见病及孤儿药的重视,并为促使我国孤儿药政策的建立提供参考。结论:我国应加快建立孤儿药政策,积极实施优惠政策促进我国孤儿药的研发。 Objective: Understanding aboul the rare diseases and orphan drug situation in our county. The successful experience to draw on international orphan drug management system to make recommendations on the establishment of orphan drugs policy. Methods: Comparative analysis of foreign orphan drug management system through the literature search, According to China orphan drug problems in the proposed poliey-making method. Results: Overview of rare diseases and orphan drug status quo in China and its international policies and regulations, the successful experienee, has aroused more attention, professionals focus on rare diseases and orphan drugs. The paper provide a reference for the purpose of promuting the establishment of orphan drug policy. Conclusion: China shouhl accelerate the establishment of orphan drug policy, Active implementation of preferential policies to promote the research and development of orphan drugs in China.
作者 刘慧敏 孟锐
出处 《中国药物评价》 2012年第2期176-179,共4页 Chinese Journal of Drug Evaluation
关键词 罕见病 孤儿药 现状 孤儿药政策 Rare diseases Orphan drugs Situation Orphan drug policy
  • 相关文献

参考文献8

二级参考文献33

  • 1李文歌,谌贻璞.α-GaIA酶替代疗法治疗Fabry病的临床应用与进展[J].世界临床药物,2005,26(2):75-78. 被引量:4
  • 2王贤才.临床药物大典[M].青岛:青岛出版社,1994.561-562. 被引量:28
  • 3曹筠武.全国紧缺凝血八因子十万血友病等待救援[EB/OL].http://www.raredisease.org.cn/view.aspx7.200807-29.2008-09-18. 被引量:1
  • 4Meyers AS. History of the American Orphan Drug Act [R] . International conference of rare disease and orphan drugs. Spain, 2000. 被引量:1
  • 5Arno PS, Bonuck K, Davis M. Rare disease, drug development, and AIDS : the impact of the Orphan Drug Act [J ]. Milbank Q, 1995, 73(2) : 231. 被引量:1
  • 6Stolk P, Willemen M J, Leufkens HG.Rare essentials: drugs for rare diseases as essential medicines[J] .Bull World Health Organ ,2006,84(9) :745. 被引量:1
  • 7叶秀珍,曾敏杰,林志鹏.各国罕见疾病相关法案之比较研究[M].台湾:中国台湾中正大学财团法人罕见疾病基金会出版,2003:23-130. 被引量:1
  • 8United States Code. Orphan Drug Act [S] .Public Law, 1983. 被引量:1
  • 9Schieppati A, Henter JI, Daina E, et al. Why rare diseases are an important medical and social issue. Lancet, 2008,371(9629): 2039-2041. 被引量:1
  • 10罕见病的定义[EB/OL].[2011-02-07].http://www.chinararedisease.cn/1-5-dingyi.html. 被引量:1

共引文献97

同被引文献77

  • 1方剑春.生产不足,需求增长-血液制品供货紧张拉响警报[N].中国医药报,2007-07-26. 被引量:4
  • 2FDA:How to Apply for Orphan Drug Designation[EB/OL].[2013-11-22].http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm365086.htm. 被引量:1
  • 3EMA.Orphan Designation[EB/OL].[2013-11-22].http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&mid=WC0b01ac05800240ce. 被引量:1
  • 4陈一昀.罕见病特效药或将进医保目录[N].新金融观察,2012-06-11(29). 被引量:1
  • 5我国加大生物医药的投资力度[EB/OL].(2007-06-13)[2013-11-22].http://finance.sina.com.cn/chanjing/b/20070613/13223688158.shtml. 被引量:1
  • 6中国外商投资企业协会药品研制和开发行业委员会.全力提升中国医药产业创新能力研究报告[R].2012. 被引量:1
  • 7Braun M M,Farag-El-Massah S,Xu K,et al.Emergence of Orphan Drugs in the United States:A Quantitative Assessment of the First 25 years[J].Nature Reviews Drug Discovery,2010,9(7):519-522. 被引量:1
  • 8Rohde D D.Orphan Drug Act:An Engine of Innovation-At What Cost,The[J].Food&Drug LJ,2000,55:125-126. 被引量:1
  • 9Denis A,Mergaert L,Fostier C,et al.A Comparative Study of European Rare Disease and Orphan Drug Markets[J].Health Policy,2010,97(2):173-179. 被引量:1
  • 10Heemstra H E,van Weely S,Büller H A,et al.Translation of Rare Disease Research into Orphan Drug Development:Disease Matters[J].Drug Discovery Today,2009,14(23):1166-1173. 被引量:1

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部